Theodore F. Logan, MD
Associate Professor of Clinical Medicine
Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results.
Discordancy in BRAF mutations among primary and metastatic melanoma lesions: clinical implications for targeted therapy.
The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.
Whole-body PET/CT evaluation of tumor perfusion using generator-based 62Cu-ethylglyoxal bis(thiosemicarbazonato)copper(II): validation by direct comparison to 15O-water in metastatic renal cell carcinoma.
A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer.